{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:21:46Z","timestamp":1777605706208,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFE0103100"],"award-info":[{"award-number":["2021YFE0103100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81521005"],"award-info":[{"award-number":["81521005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673382"],"award-info":[{"award-number":["81673382"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81925035"],"award-info":[{"award-number":["81925035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.apsb.2021.06.001","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:58:19Z","timestamp":1623110299000},"page":"3622-3635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Genetically-engineered \u201call-in-one\u201d vaccine platform for cancer immunotherapy"],"prefix":"10.1016","volume":"11","author":[{"given":"Aihua","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hairui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yisi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuangzhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-8915","authenticated-orcid":false,"given":"Yongzhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.06.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2016.11.001","article-title":"Peptide vaccines in cancer-old concept revisited","volume":"45","author":"Kumai","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.apsb.2021.06.001_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/intimm\/dxw015","article-title":"Vaccine adjuvants as potential cancer immunotherapeutics","volume":"28","author":"Temizoz","year":"2016","journal-title":"Int Immunol"},{"key":"10.1016\/j.apsb.2021.06.001_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.toxicon.2004.12.024","article-title":"Recent advances in trichosanthin, a ribosome-inactivating protein with multiple pharmacological properties","volume":"45","author":"Shaw","year":"2005","journal-title":"Toxicon"},{"key":"10.1016\/j.apsb.2021.06.001_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.biomaterials.2016.11.033","article-title":"Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: turning PEG dilemma into prodrug-like feature","volume":"116","author":"Chen","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.06.001_bib5","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.7150\/thno.20578","article-title":"Glioma dual-targeting nanohybrid protein toxin constructed by intein-mediated site-specific ligation for multistage booster delivery","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2021.06.001_bib6","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1021\/acs.molpharmaceut.6b00987","article-title":"Prodrug-like, PEGylated protein toxin trichosanthin for reversal of chemoresistance","volume":"14","author":"Chen","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.06.001_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1615\/CritRevOncog.v18.i1-2.70","article-title":"The tumor microenvironment: a target for combination therapy of breast cancer","volume":"18","author":"Reisfeld","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.apsb.2021.06.001_bib8","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1172\/JCI27648","article-title":"Targeting tumor-associated macrophages as a novel strategy against breast cancer","volume":"116","author":"Luo","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2021.06.001_bib9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.biochi.2015.09.022","article-title":"Structure and function of legumain in health and disease","volume":"122","author":"Dall","year":"2016","journal-title":"Biochimie"},{"key":"10.1016\/j.apsb.2021.06.001_bib10","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1002\/adma.201403547","article-title":"Molecular-dynamics-simulation-driven design of a protease-responsive probe for in-vivo tumor imaging","volume":"26","author":"Jiang","year":"2014","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2021.06.001_bib11","article-title":"Expression of legumain correlates with prognosis and metastasis in gastric carcinoma","volume":"8","author":"Guo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.06.001_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2014.10.020","article-title":"High expression of the cysteine proteinase legumain in colorectal cancer\u2014implications for therapeutic targeting","volume":"51","author":"Haugen","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2021.06.001_bib13","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1172\/JCI27648","article-title":"Targeting tumor-associated macrophages as a novel strategy against breast cancer","volume":"116","author":"Luo","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2021.06.001_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00262-007-0389-x","article-title":"A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis","volume":"57","author":"Lewen","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2021.06.001_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/CJI.0000000000000040","article-title":"Enhancement of DNA vaccine potency against legumain","volume":"37","author":"Smahel","year":"2014","journal-title":"J Immunother"},{"key":"10.1016\/j.apsb.2021.06.001_bib16","first-page":"E19","article-title":"Low molecular weight protamine as nontoxic heparin\/low molecular weight heparin antidote (III): preliminary in\u00a0vivo evaluation of efficacy and toxicity using a canine model","volume":"3","author":"Lee","year":"2001","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.apsb.2021.06.001_bib17","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1002\/anie.200906153","article-title":"Synthetic skin-permeable proteins enabling needleless immunization","volume":"49","author":"Huang","year":"2010","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2021.06.001_bib18","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1039\/c2jm00121g","article-title":"Skin-permeable quaternary nanoparticles with layer-by-layer structure enabling improved gene delivery","volume":"22","author":"Yang","year":"2012","journal-title":"J Mater Chem"},{"key":"10.1016\/j.apsb.2021.06.001_bib19","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1016\/j.biomaterials.2012.07.061","article-title":"The effect of epidermal growth factor (EGF) conjugated with low-molecular-weight protamine (LMWP) on wound healing of the skin","volume":"33","author":"Choi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.06.001_bib20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.addr.2012.11.007","article-title":"Curb challenges of the \"Trojan Horse\" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery","volume":"65","author":"Huang","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.06.001_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1389201015666140617094320","article-title":"Cell-penetrating peptide-mediated topical delivery of biomacromolecular drugs","volume":"15","author":"Tan","year":"2014","journal-title":"Curr Pharmaceut Biotechnol"},{"key":"10.1016\/j.apsb.2021.06.001_bib22","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.bbrc.2009.12.006","article-title":"Low-density lipoprotein receptor-related protein 1 is an essential receptor for trichosanthin in 2 choriocarcinoma cell lines","volume":"391","author":"Jiao","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2021.06.001_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cytogfr.2014.07.018","article-title":"The IL-2 cytokine family in cancer immunotherapy","volume":"25","author":"Sim","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.apsb.2021.06.001_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.apsb.2021.06.001_bib25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","article-title":"TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression","volume":"31","author":"Yang","year":"2010","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2021.06.001_bib26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s10875-008-9240-1","article-title":"Role of TGF-\u03b2 in the induction of Foxp3 expression and T regulatory cell function","volume":"28","author":"Shevach","year":"2008","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.apsb.2021.06.001_bib27","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/82225","article-title":"Transcutaneous immunization: a human vaccine delivery strategy using a patch","volume":"6","author":"Glenn","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2021.06.001_bib28","doi-asserted-by":"crossref","first-page":"1700666","DOI":"10.1002\/smll.201700666","article-title":"Microneedle-assisted, DC-targeted codelivery of pTRP-2 and adjuvant of paclitaxel for transcutaneous immunotherapy","volume":"13","author":"Xu","year":"2017","journal-title":"Small"},{"key":"10.1016\/j.apsb.2021.06.001_bib29","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/82383","article-title":"Efficient nonviral transfection of dendritic cells and their use for in\u00a0vivo immunization","volume":"18","author":"Irvine","year":"2000","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2021.06.001_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejpb.2016.12.033","article-title":"Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy","volume":"114","author":"Even","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.06.001_bib31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2017.52","article-title":"A STING-activating nanovaccine for cancer immunotherapy","volume":"12","author":"Luo","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2021.06.001_bib32","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.apsb.2020.08.010","article-title":"Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy","volume":"10","author":"Zhu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.06.001_bib33","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI69999","article-title":"Targeting immunosuppression for cancer therapy","volume":"123","author":"Ghirelli","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2021.06.001_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.imlet.2007.03.008","article-title":"Up-regulation of IL-10 expression in dendritic cells is involved in trichosanthin-induced immunosuppression","volume":"110","author":"Zhou","year":"2007","journal-title":"Immunol Lett"},{"key":"10.1016\/j.apsb.2021.06.001_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/cmi.2011.12","article-title":"Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM","volume":"8","author":"Cai","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2021.06.001_bib36","first-page":"297","article-title":"Trichosanthin induced Th2 polarization status","volume":"3","author":"Zhao","year":"2006","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2021.06.001_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cellimm.2015.02.003","article-title":"Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer","volume":"294","author":"Zheng","year":"2015","journal-title":"Cell Immunol"},{"key":"10.1016\/j.apsb.2021.06.001_bib38","doi-asserted-by":"crossref","first-page":"26460","DOI":"10.18632\/oncotarget.15518","article-title":"Trichosanthin increases Granzyme B penetration into tumor cells by upregulation of CI-MPR on the cell surface","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2021.06.001_bib39","first-page":"290","article-title":"Preparation of anticolon carcinoma vaccine with rich chaperone peptides and study on its anticancer efficacy","volume":"12","author":"Zhao","year":"2009","journal-title":"Chin J Gastrointest Surg"},{"key":"10.1016\/j.apsb.2021.06.001_bib40","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2021.06.001_bib41","doi-asserted-by":"crossref","first-page":"119929","DOI":"10.1016\/j.ijpharm.2020.119929","article-title":"Targeted delivery of zoledronic acid through the sialic acid\u2012Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages\u2014a promising cancer immunotherapy","volume":"590","author":"Tang","year":"2020","journal-title":"Int J Pharm"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521002136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521002136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:52:58Z","timestamp":1761929578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2211383521002136"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.06.001","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetically-engineered \u201call-in-one\u201d vaccine platform for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}